keyword
MENU ▼
Read by QxMD icon Read
search

Plaque psoriasis

keyword
https://www.readbyqxmd.com/read/29156950/management-of-moderate-to-severe-plaque-psoriasis-the-emerging-role-of-il-17-inhibition
#1
Robert Bissonnette, Marc Bourcier, Melinda Gooderham, Chih-Ho Hong, Ian Landells, Charles Lynde, Kim Papp, Yves Poulin, Ronald Vender, Marni C Wiseman
No abstract text is available yet for this article.
September 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/29146007/-psoriatic-arthritis-in-france-from-infants-to-the-elderly-findings-from-two-cross-sectional-multicenter-studies
#2
A Galezowski, F Maccari, S Hadj-Rabia, M-L Sigal, A Phan, M Lahfa, A-C Bursztejn, H Barthélémy, F Boralévi, Z Reguiai, C Chiavérini, E Estève, E Bourrat, M Ruer-Mulard, A Beauchet, E Mahé
BACKGROUND: Psoriatic arthritis affects 20-30% of patients with psoriasis. Few epidemiological data are available in France about its prevalence and its association with skin lesions and comorbidities. OBJECTIVES: To assess the epidemiological aspects and the risk factors for psoriatic arthritis in children and adults in France. METHODS: Two cross-sectional studies were conducted in France in children (χ-Psocar, 23 pediatric dermatology centers belonging to the SFDP, 1 year) and adults (Resopsocar, 29 dermatology centers belonging to GEM RESOPSO, 4 months) to study the link between psoriasis and cardiovascular and metabolic comorbidities...
November 13, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29145701/tnf-antagonists-killing-two-birds-with-one-biologic-stone
#3
EDITORIAL
Joan M Bathon, Jon T Giles, Daniel H Solomon
Forty years have passed since it was first recognized that patients with autoimmune rheumatic disease have an increased risk of fatal and non-fatal cardiovascular (CV) events (1) Although initial reports focused on rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), similar findings were verified subsequently in patients with psoriasis (Ps) and/or psoriatic arthritis (PsA) and spondyloarthritis. An early feature of the atherosclerotic lesion is infiltration with inflammatory cells, particularly monocytes/macrophages, and the presence of these cells in mature plaque elevates the risk of plaque rupture and thrombosis (2)...
November 16, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29144096/long-term-treatment-with-etanercept-monotherapy-in-a-hemodialyzed-patient-with-moderate-to-severe-plaque-type-psoriasis-and-psoriatic-arthritis
#4
Graziella Babino, Maria Esposito, Luca Bianchi, Alessandro Giunta
No abstract text is available yet for this article.
November 16, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29143230/the-efficacy-of-biologic-therapy-for-the-management-of-palmoplantar-psoriasis-and-palmoplantar-pustulosis-a-systematic-review
#5
REVIEW
Isabelle M Sanchez, Eric Sorenson, Ethan Levin, Wilson Liao
INTRODUCTION: Palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP) are diseases affecting the hands and/or feet that can cause marked physical discomfort and functional disability. The tumor necrosis factor-alpha antagonists adalimumab, etanercept, and infliximab, the interleukin (IL)-17A inhibitors ixekizumab and secukinumab, and the IL-23 or IL-12/IL-23 inhibitors guselkumab and ustekinumab have been well studied for the treatment of moderate to severe plaque psoriasis. Less is known about the efficacy and safety of these agents for the treatment of PP (hyperkeratotic and pustular forms) and PPP...
December 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/29136293/efficacy-and-safety-of-tofacitinib-for-moderate-to-severe-plaque-psoriasis-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#6
REVIEW
C-M Kuo, T-H Tung, S-H Wang, C-C Chi
The effects of tofacitinib in treating moderate-to-severe plaque psoriasis were unclear. We aimed to assess the effects of tofacitinib in treating moderate-to-severe plaque psoriasis. We searched PubMed, Cochrane Central Register of Controlled Trials, and EMBASE for relevant randomised controlled trials (RCTs), and conducted a systematic review and meta-analysis. Four RCTs with 2,724 participants were included. Compared to placebo, tofacitinib significantly improved psoriasis (≥ 75% reduction in the Psoriasis Area and Severity Index score: 5 mg BID: risk difference (RD) 0...
November 14, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29134822/treating-moderate-to-severe-plaque-psoriasis-with-guselkumab-a-review-of-phase-ii-and-phase-iii-trials
#7
Seth T Howell, Leah A Cardwell, Steven R Feldman
OBJECTIVE: Guselkumab, an anti-interleukin-23 monoclonal antibody was recently approved for the treatment of patients with moderate-to-severe plaque psoriasis. This article will review the available phase II and phase III guselkumab clinical trial data. DATA SOURCES: A PubMed search was conducted using the terms guselkumab, interleukin-23, psoriasis, adalimumab, and ustekinumab (January 2014 to August 2017). STUDY SELECTION AND DATA EXTRACTION: Articles detailing the results of phase II and phase III clinical trials were selected for review...
November 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29134613/dfd-01-reduces-transepidermal-water-loss-and-improves-skin-hydration-and-flexibility
#8
J Mark Jackson, Gary L Grove, Kent Allenby, Tim Houser
INTRODUCTION: In plaque psoriasis, the benefit of topical steroids is well established. The vehicle formulation of topical steroids may also provide benefit in addition to the effects of the steroid itself. DFD-01 (betamethasone dipropionate spray, 0.05%) is a formulation composed of a topical steroid in an emollient-like vehicle that enhances penetration to the target site of inflammation in the skin. The aim of this study was to assess the effect of DFD-01 and its vehicle on skin hydration and barrier function in compromised skin and to evaluate its effect on flexibility in healthy skin...
December 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/29132853/assessing-clinical-response-and-defining-minimal-disease-activity-in-plaque-psoriasis-with-the-physician-global-assessment-and-body-surface-area-pga%C3%A2-%C3%A3-%C3%A2-bsa-composite-tool-an-analysis-of-apremilast-phase-3-esteem-data
#9
Alice B Gottlieb, Joseph F Merola, Rongdean Chen, Eugenia Levi, Kristina Callis Duffin
No abstract text is available yet for this article.
December 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29129905/change-of-oral-to-topical-corticosteroid-therapy-exacerbated-glucose-tolerance-in-a-patient-with-plaque-psoriasis
#10
Yui Hongo, Kenji Ashida, Kenji Ohe, Munechika Enjoji, Miyuki Yamaguchi, Tsuyoshi Kurata, Akiko Emoto, Hiroko Yamanouchi, Satoko Takagi, Hitoe Mori, Nozomi Kawata, Yoshio Hisata, Yuta Sakanishi, Kenichi Izumi, Takashi Sugioka, Keizo Anzai
BACKGROUND Psoriasis is known as the most frequent disease treated by long-term topical steroids. It is also known that patients with thick, chronic plaques require the highest potency topical steroids. However, the treatment is limited to up to four weeks due to risk of systemic absorption. CASE REPORT An 80-year-old man was diagnosed with type 2 diabetes 16 years before, and was being administered insulin combined with alpha glucosidase inhibitor. He was diagnosed with plaque psoriasis and his oral steroid treatment was switched to topical steroid treatment due to lack of improvement and poorly controlled blood glucose level...
November 13, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29114862/fumaric-acid-esters-in-combination-with-a-6-week-course-of-narrow-band-uvb-provides-for-an-accelerated-response-as-compared-to-fumaric-acid-esters-monotherapy-in-patients-with-moderate-to-severe-plaque-psoriasis-a-randomized-prospective-clinical-study
#11
S Tzaneva, A Geroldinger, H Trattner, A Tanew
BACKGROUND: Fumaric acid esters are (FAE) safe and effective in patients with moderate to severe psoriasis but have a slow onset of action. A short-term combination with narrow-band UVB (NB UVB) may substantially accelerate the therapeutic response in the induction phase of treatment. OBJECTIVES: To assess the synergistic effect of a 6-week course of NB UVB phototherapy in addition to fumaric acid esters in adult patients with moderate to severe plaque psoriasis...
November 8, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29106714/pharmacokinetics-immunogenicity-and-efficacy-of-etanercept-in-pediatric-patients-with-moderate-to-severe-plaque-psoriasis
#12
Richard G Langley, Sree Kasichayanula, Mona Trivedi, Girish A Aras, Arunan Kaliyaperumal, Theresa Yuraszeck, John Gibbs, Megan Gibbs, Greg Kricorian, Amy S Paller
Etanercept has been recently approved in the United States for the treatment of moderate to severe plaque psoriasis in patients aged 4-17 years. The objective of this study was to characterize etanercept pharmacokinetics, immunogenicity, and efficacy in pediatric patients. Data from a phase 3 study and open-label extension study were analyzed. Etanercept serum concentrations in pediatric patients receiving etanercept 0.8 mg/kg (maximum, 50 mg) weekly were compared with adult psoriasis patients and pediatric patients with juvenile idiopathic arthritis (JIA) who received etanercept 0...
November 6, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29105621/adalimumab-etanercept-and-ustekinumab-for-treating-plaque-psoriasis-in-children-and-young-people-systematic-review-and-economic-evaluation
#13
Ana Duarte, Teumzghi Mebrahtu, Pedro Saramago Goncalves, Melissa Harden, Ruth Murphy, Stephen Palmer, Nerys Woolacott, Mark Rodgers, Claire Rothery
BACKGROUND: Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab (HUMIRA(®), AbbVie, Maidenhead, UK), etanercept (Enbrel(®), Pfizer, New York, NY, USA) and ustekinumab (STELARA(®), Janssen Biotech, Inc., Titusville, NJ, USA) are the three biological treatments currently licensed for psoriasis in children. OBJECTIVE: To determine the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and ustekinumab within their respective licensed indications for the treatment of plaque psoriasis in children and young people...
November 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/29103330/a-new-class-of-therapeutic-biologic-agents-for-combatting-psoriasis-anti-il-23-agents
#14
Annalisa Tonini, Bruno Gualtieri, Salvatore Panduri, Marco Romanelli, Andrea Chiricozzi
Psoriasis is a chronic inflammatory skin disease whose pathogenesis is driven by multiple cytokine-mediated pathways. In this immunologic setting, the centrality of the IL-23/IL-17 axis and its therapeutic relevance has emerged. Areas covered: This review is aimed at collecting preliminary data on IL23p19 blockers developed for the treatment of plaque psoriasis. Three agents, guselkumab, risankizumab, and tildrakizumab, are currently being tested in phase III trials, while LY2525623 is currently being tested in phase II trials...
November 6, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29101128/oral-chinese-herbal-medicine-for-psoriasis-vulgaris-protocol-for-a-randomised-double-blind-double-dummy-multicentre-clinical-trial
#15
Jingwen Deng, Danni Yao, Chuanjian Lu, Zehuai Wen, Yuhong Yan, Ziyang He, Huimei Wu, Hao Deng
INTRODUCTION: Psoriasis vulgaris is a common skin disease that is characterised by persistent localised erythematous scaly plaques. Yinxieling is a Chinese herbal formula for psoriasis that has been used for more than 20 years in China. To facilitate application, PSORI-CM01 was developed based on the optimisation and simplification of Yinxieling tablets performed in a previous study and in clinical practice. However, the scientific evidence regarding whether PSORI-CM01 is more effective for psoriasis than the original Yinxieling remains insufficient...
November 3, 2017: BMJ Open
https://www.readbyqxmd.com/read/29094341/safety-efficacy-and-drug-survival-of-biologics-and-biosimilars-for-moderate-to-severe-plaque-psoriasis
#16
A Egeberg, M B Ottosen, R Gniadecki, S Broesby-Olsen, T N Dam, L E Bryld, M K Rasmussen, L Skov
BACKGROUND: Real-life data on newer biologic and biosimilar agents for moderate-to-severe psoriasis are lacking. OBJECTIVES: To examine safety, efficacy, and time to discontinuation (drug survival) of biologics (adalimumab, etanercept, infliximab, secukinumab, and ustekinumab) and compare originators with biosimilars (i.e. Enbrel with Benepali, and Remicade with Remsima). METHODS: The DERMBIO registry contains data on all Danish patients with moderate-to-severe plaque psoriasis treated with biologics...
November 1, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29094282/tofacitinib-a-new-oral-therapy-for-psoriasis
#17
REVIEW
Alexandra Azevedo, Tiago Torres
Psoriasis is a common, chronic, immune-mediated disease associated with several comorbidities. Biologic therapy revolutionized the treatment of moderate-to-severe psoriasis, improving physical and emotional burden of the disease. Still, there are unmet needs in the treatment of psoriasis regarding long-term efficacy, tolerability, safety, route of administration, and cost. The increased knowledge of the pathogenesis of the intracellular metabolic pathways allowed the development of new compounds that inhibit certain intracellular proteins involved in the immune response...
November 1, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29091929/the-cathelicidin-protein-cramp-is-a-potential-atherosclerosis-self-antigen-in-apoe-mice
#18
Peter M Mihailovic, Wai Man Lio, Juliana Yano, Xiaoning Zhao, Jianchang Zhou, Kuang-Yuh Chyu, Prediman K Shah, Bojan Cercek, Paul C Dimayuga
Auto-immunity is believed to contribute to inflammation in atherosclerosis. The antimicrobial peptide LL-37, a fragment of the cathelicidin protein precursor hCAP18, was previously identified as an autoantigen in psoriasis. Given the reported link between psoriasis and coronary artery disease, the biological relevance of the autoantigen to atherosclerosis was tested in vitro using a truncated (t) form of the mouse homolog of hCAP18, CRAMP, on splenocytes from athero-prone ApoE(-/-) mice. Stimulation with tCRAMP resulted in increased CD8+ T cells with Central Memory and Effector Memory phenotypes in ApoE(-/-) mice, differentially activated by feeding with normal chow or high fat diet...
2017: PloS One
https://www.readbyqxmd.com/read/29090236/expression-of-th1-and-th2-cytokine-and-associated-transcription-factors-in-peripheral-blood-mononuclear-cells-and-correlation-with-disease-severity
#19
Hadis Yousefzadeh, Farahzad Jabbari Azad, Maryam Rastin, Mahnaz Banihashemi, Mahmoud Mahmoudi
BACKGROUND: Psoriasis is a T cell-mediated autoimmune disease in patients with elevated levels of proinflammatory cytokines belonging mainly to the Th1 pathway. We investigated whether treatment of psoriasis patients with methotrexate (MTX), along with micronutrients, modulated mRNA expression of Th1 and Th2 components and whether expression of these components correlated with psoriasis severity. METHODS: Thirty plaque-type psoriasis patients with Psoriasis Area and Severity Index (PASI) scores greater than 10 were recruited; these were 15 non-micronutrients taking- (NMT) patients treated with MTX daily (0...
October 2017: Reports of Biochemistry & Molecular Biology
https://www.readbyqxmd.com/read/29090075/lentiginous-eruption-in-resolving-psoriasis-plaques-during-treatment-with-ixekizumab-a-case-report-and-review-of-the-literature
#20
Pablo Santa María, Fernando Valenzuela, Claudia Morales, Raul De la Fuente, Roberto Cullen
No abstract text is available yet for this article.
October 11, 2017: Dermatology Reports
keyword
keyword
82378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"